Stem Cell Therapeutics Corp. (TSX VENTURE:SSS), a life sciences company developing stem cell-related technologies, today announced the signing of an agreement with University Health Network (UHN), through its commercialization agent MaRS Innovation (MI), both of Toronto.
The agreement provides Stem Cell Therapeutics ("SCT") with an option to an exclusive world-wide license to an innovative cancer stem cell program.
This agreement produced a license for a UHN technology on April 17, 2013.
Yonge Street Media, a weekly online magazine that covers talent, innovation, diversity and quality of life stories in the Toronto region, covered Bedside Clinical Systems' (BCS) launch in their Innovation section on Wednesday, November 7, 2012.
BCS is a MaRS Innovation spin-off company created to commercialize decision-support research emerging from The Hospital for Sick Children (SickKids). (more…)
Each year, 5,000 children in North American hospitals experience code-blue incidents; a code blue is an event where patients require immediate resuscitation.
One quarter of these incidents result in death, and Bedside Clinical Systems (BCS) seeks to drastically improve this statistic by launching its flagship solution, Bedside Paediatric Early Warning System (BedsidePEWS™).
“BedsidePEWS™ is a unique software solution that helps hospital clinicians to identify deteriorating children early, giving them a window of opportunity to intervene and potentially avoid code blue incidents,” says Rajesh ...
Matt Ratto, assistant professor in the University of Toronto's Faculty of Information and co-inventor and CEO of Shotlst, a UTEST company, was featured in the Globe and Mail on October 22 in an article by Nick Rockel on how emerging technology will change the education experience.
Here's an excerpt:
Asked what the technological tools in university classrooms will look and feel like by 2020, Matt Ratto admits he’s no futurist. But the assistant professor at the University of Toronto’s Faculty of Information is ...
Welcome to the beta version of the MaRS Innovation website.
We have refreshed the site's design to make better use of its existing functionality while showcasing our projects.
The new design includes these additions and changes: (more…)
Un partenariat visant à investir jusqu’à 1 M$ dans les découvertes canadiennes prometteuses en matière de soins de santé
TORONTO (Ontario), le 4 octobre 2012 – Baxter International Inc. et MaRS Innovation, un centre d’excellence en commercialisation et en recherche, ont établi un partenariat stratégique afin de commercialiser des technologies en phase de développement qui constituent des méthodes novatrices sur le plan des technologies thérapeutiques et de découverte de médicaments.
Information about MaRS Innovation and Baxter's partnership is also available in English.
MaRS Innovation and York University’s commercialization office support new partnership
In the age of ITunes, videotaping lectures or converting existing textbooks into e-books won’t make you the market leader in online education.
Thanks to a new partnership between ClevrU, and NewMindsets Inc., facilitated by MaRS Innovation and York University’s commercialization office, Canadian technology and content promises to establish the second-generation online learning standard for millions of students worldwide. (more…)
TORONTO, ON – A new program that provides nascent software companies with start-up funds, work space, mentoring and business strategy support, was launched today by the University of Toronto and commercialization partner MaRS Innovation, with support from the MaRS Discovery District.
TechVibes has a profile page for UTEST and covered CoursePeer as part of their students start-ups series.
The new program, called University of Toronto Early Stage Technology (UTEST), is part of a growing ecosystem of incubators and commercialization support services at U ...
ScarX Therapeutics, a spin-off company created by MaRS Innovation and The Hospital for Sick Children (SickKids), was profiled by Business Without Borders on September 25, 2012.
Sean Fine's article examines the strategic funding partnership MI pursued with NovoTek Therapeutics Inc. (NovoTek) in China to develop the anti-scarring cream, which was discovered by researchers at SickKids.
A multibillion-dollar market may await ScarX, a Toronto biomedical start-up, but first it had to figure out how to finance the development of its unique cream that reduces scarring ...